What does my HER2-Low Breast Cancer biomarker profile mean for treatment options

Understanding Your HER2-Low Breast Cancer Profile

Thank you for asking about this important biomarker. HER2-low breast cancer is a distinct category that has opened up new treatment possibilities in recent years, and understanding your profile will help you have more informed conversations with your care team.

What HER2-Low Means

HER2 is a protein that sits on the surface of breast cancer cells and can drive cancer growth. Your HER2-low status means your cancer has:

• IHC (immunohistochemistry) score of 1+ or 2+ — these are lower levels of HER2 protein expression compared to HER2-positive (3+) cancers
• Cancer cells that express some HER2, but not at the high levels traditionally targeted by older HER2 therapies

This is clinically important because, historically, doctors primarily treated patients with HER2 3+ (high) cancers with HER2-targeted drugs. Your HER2-low status was often considered "HER2-negative" and treated differently — until recently.

The Clinical Significance: A Recent Breakthrough

According to NCCN Guidelines, a major shift occurred with the FDA approval of trastuzumab deruxtecan (Enhertu), an antibody-drug conjugate (ADC). This is a newer type of HER2-targeted therapy that works differently than older drugs:

• How it works: It's an antibody that carries chemotherapy directly to HER2-expressing cancer cells, then releases the chemotherapy inside the cell
• Why it matters for HER2-low: Clinical trials showed that patients with HER2-low breast cancer (IHC 1+ or 2+) had significantly better outcomes with this drug compared to chemotherapy alone
  • Overall survival: 24 months with Enhertu vs. 17 months with chemotherapy alone

This represents a meaningful survival benefit and has "opened the floodgates" for treatment options in the HER2-low population.

How Doctors Think About Your Case

STEP 1 — Clinical Decision-Making Framework:

Your oncologist will consider:

1. Your hormone receptor status (ER/PR positive or negative?) — this is crucial because it determines whether hormone therapy is also an option
2. Stage of disease (early-stage vs. metastatic/advanced)
3. Whether you've had prior treatments and how your cancer responded
4. Your overall health and ability to tolerate treatment

According to NCCN Guidelines for Invasive Breast Cancer, the approach differs based on these factors.

STEP 2 — General Treatment Approaches That Exist:

For patients with HER2-low breast cancer, doctors typically consider:

If hormone receptor-positive (HR+/ER+ or PR+):

• Endocrine therapy (hormone-blocking drugs like tamoxifen, aromatase inhibitors, or fulvestrant)
• CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib) combined with hormone therapy — these help control cancer longer
• Potentially Enhertu in addition to hormone therapy (depending on stage and response)

If hormone receptor-negative (HR-/ER- and PR-):

• Chemotherapy may be the primary approach
• Enhertu is increasingly being used for HER2-low, HR-negative cancers
• Immunotherapy options may be considered (particularly for triple-negative breast cancer)

If metastatic (advanced) disease:

• According to NCCN Guidelines for Metastatic Breast Cancer, treatment is individualized based on:
  • Whether you're in "visceral crisis" (organs severely affected)
  • Prior treatments and how long ago
  • Your specific mutations and biomarkers

Questions to Ask Your Oncologist

To help you engage in shared decision-making about YOUR specific situation:

1. "Based on my hormone receptor status and stage, which treatment approach do you recommend for me, and why?"

2. "Am I a candidate for Enhertu (trastuzumab deruxtecan)? What would be the benefits and side effects for my specific case?"

3. "If I'm HR-positive, would combining hormone therapy with a CDK4/6 inhibitor be appropriate for me?"

4. "What is the goal of treatment — to cure the cancer, control it long-term, or manage symptoms? How will we measure if treatment is working?"

5. "Are there any clinical trials available for HER2-low breast cancer that might be appropriate for me?"

6. "What side effects should I expect, and how will we monitor my heart health during treatment?" (HER2-targeted therapies require heart monitoring)

Important Context

The NCCN Guidelines emphasize that your complete clinical picture matters:

• Your specific hormone receptor results
• Whether cancer is in lymph nodes or has spread
• Your age and overall health
• Any other genetic mutations (like BRCA status)
• Prior treatments you've received

All of these factors influence which specific treatment your doctor will recommend.

Why This Matters

Your HER2-low status is actually good news in one important way: it means you have more treatment options available now than patients with this profile had just a few years ago. The approval of Enhertu specifically for HER2-low cancers represents a genuine advance in precision medicine — matching the right drug to your specific biomarker profile.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines for Invasive Breast Cancer (2024-2025)
• NCCN Guidelines for Metastatic Breast Cancer (2024)
• NCCN Guidelines for Patients: Invasive Breast Cancer
• CancerPatientLab Webinar: "Proteomic Testing for Cancer: How Protein Analysis Guides Treatment" (Sheeno Thyparambil) — discussing HER2-low treatment advances and Enhertu approval